Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 06/20 12:57:20 pm
17.14 EUR   -0.81%
04/24PCAS : Chiffre d'affaires au 31 Mars 2018
PU
04/24PCAS : Net sales as of march 31, 2018
GL
04/24PCAS : 1st quarter earnings
CO
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

PCAS : quarterly financial reporting Sep 30, 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2011 | 05:40pm CEST

Quarterly financial reporting
As of 30 September 2011

 

 

Business update

 

(in thousands of euros)20112010% change
 First Quarter44,05341,4346,3%
 including Pharmaceutical Synthesis27,14726,6032,0%
 including Specialty Chemicals16,90614,83114,0%
 Second Quarter41,78942,698-2,1%
 including Pharmaceutical Synthesis26,45728,100-5,8%
 including Specialty Chemicals15,33214,5985,0%
 Third Quarter33,48133,658-0,5%
 including Pharmaceutical Synthesis19,53018,3946,2%
 including Specialty Chemicals13,95115,264-8,6%
 Total as of 30 September119,323117,7901,3%
 including Pharmaceutical Synthesis73,13473,0970,1%
 including Specialty Chemicals46,18944,6933,3%

 

 

 

The PCAS Group's consolidated revenues at 30 September 2011came in 1.3% higher than the same period the previous year.

 

Pharmaceutical Synthesis
Over the first five months of the year, business was affected by the planned reduction in the contribution by the new contract between PCAS and Sanofi, effective since 31 May 2010. Excluding this contract, the Exclusive and Non-Exclusive Pharma business is up 10.5% at 30 September 2011.
Fine Specialty Chemicals
With growth of 3.3% at 30 September 2011, the Fine Specialty Chemicals business contracted by 8.6% during the third quarter of 2011 in relation to 2010, reflecting the economic slowdown seen since the summer.

 

Key operations and events for the quarter

 

No important events likely to have a significant impact on the company's business or situation occurred during the third quarter of 2011.

 

Outlook for the current year

 

The high level of sales expected for the fourth quarter should lead to earnings growth in 2011.

 

 

Next date :  2011 earnings, February 22nd, 2012

 

 

About PCAS
PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.

 

Longjumeau, October 7th, 2011

 

PCAS_T3_2011_EN:
http://hugin.info/143512/R/1553112/478624.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE

HUG#1553112
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
04/24PCAS : Chiffre d'affaires au 31 Mars 2018
PU
04/24PCAS : Net sales as of march 31, 2018
GL
04/24PCAS : 1st quarter earnings
CO
02/20PCAS : 2017 Annual Results
GL
02/15PCAS SA : annual earnings release
01/31PCAS : Net sales as of December 31, 2017
PU
01/31PCAS : Net sales as of december 31, 2017
GL
01/31PCAS : Net sales as of december 31, 2017
AQ
2017PCAS : Chiffre d'affaires au 30 septembre 2017
PU
2017PCAS : Résultats au 1er semestre 2017
PU
More news
Financials (€)
Sales 2018 227 M
EBIT 2018 20,6 M
Net income 2018 10,2 M
Debt 2018 47,9 M
Yield 2018 -
P/E ratio 2018 23,83
P/E ratio 2019 21,20
EV / Sales 2018 1,37x
EV / Sales 2019 1,29x
Capitalization 263 M
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 18,8 €
Spread / Average Target 8,5%
EPS Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Pierre Luzeau Chairman
Pierre Schreiner Chief Operating Officer
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Scientific Director
Sector and Competitors
1st jan.Capitalization (M$)
PCAS-4.64%304
JOHNSON & JOHNSON-13.17%325 398
PFIZER-0.17%211 520
NOVARTIS-8.25%188 977
ROCHE HOLDING LTD.-14.38%182 331
MERCK AND COMPANY8.46%164 082